公开(公告)号：WO2022129120A1

公开(公告)日：2022-06-23

申请号：PCT/EP2021/085810

申请日：2021-12-15

申请人： F. HOFFMANN-LA ROCHE AG ,  HOFFMANN-LA ROCHE INC.

发明人： BUJOTZEK, Alexander ,  CARPY GUTIERREZ CIRLOS, Alejandro ,  FREIMOSER-GRUNDSCHOBER, Anne ,  HAGE, Carina ,  HOFER, Thomas ,  KIRCHNER, Silke ,  MAJETY, Meher ,  MOESSNER, Ekkehard ,  NEUMANN, Christiane ,  SPICK, Christian ,  TIEFENTHALER, Georg ,  WEINDL, Thomas

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61P37/02 ,  A61K39/00

摘要： The present invention relates antibodies that bind to human HLA- G, multispecific antibodies thereof, their preparation, formulations and methods of using the same. In particular, specific variants of the antibody designated HLA-G-0090 are provided with mutations in the CDR1 of the variable region of the light chain (CDR-L1) which comprises a potential glycosylation site (NSS). Two particular variants showed improved binding properties, good expressability and stability, while showing no more N-glycosylation at the CDR-L1 of the light chain (so no Fab glycosylation could be detected). In one embodiment bispecific antibodies are disclosed comprising the variants for the HLA-G antibody and an antibody binding human CD3.

公开(公告)号：WO2019166432A1

公开(公告)日：2019-09-06

申请号：PCT/EP2019/054729

申请日：2019-02-26

申请人： F. HOFFMANN-LA ROCHE AG ,  HOFFMANN-LA ROCHE INC.

发明人： POESCHINGER, Thomas ,  RIES, Carola ,  SHEN, Hong ,  YUN, Hongying ,  HOVES, Sabine ,  HAGE, Carina

IPC分类号： A61K31/522 ,  A61P35/00

摘要： The present invention relates to compounds of formula (I), wherein R 1 , R 2 and R 3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, for (use in) the treatment and/or prophylaxis of liver cancer.

公开(公告)号：WO2020089209A1

公开(公告)日：2020-05-07

申请号：PCT/EP2019/079494

申请日：2019-10-29

申请人： F. HOFFMANN-LA ROCHE AG ,  HOFFMANN-LA ROCHE INC.

发明人： POESCHINGER, Thomas ,  RIES, Carola ,  HOVES, Sabine ,  HAGE, Carina ,  KIESSLING, Fabian

IPC分类号： A61K31/00 ,  A61K31/44 ,  A61P35/00 ,  G01N33/00

摘要： The application relates to methods of treating cancer in a patient using kinase inhibitors, as well as methods of predicting the response of a cancer to treatment with a kinase inhibitor. In one embodiment, the method comprises determining the level of macrophages, and optionally the level of NK cells, in a tumour sample obtained from the patient. In addition, or alternatively, a method of predicting the response of a cancer to treatment with a kinase inhibitor may comprise determining the level of interleukin-1 β (IL-Ιβ) and/or interleukin-18 (IL-18) in a sample obtained from the patient.